- Home
- STRK vs WGSWW Comparison
STRK vs WGSWW Comparison
Compare STRK & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRK
- WGSWW
- Stock Information
- Founded
- STRK 1989
- WGSWW 2017
- Country
- STRK United States
- WGSWW United States
- Employees
- STRK 1534
- WGSWW 1000
- Industry
- STRK
- WGSWW Retail: Computer Software & Peripheral Equipment
- Sector
- STRK
- WGSWW Technology
- Exchange
- STRK NYSE
- WGSWW Nasdaq
- Market Cap
- STRK N/A
- WGSWW N/A
- IPO Year
- STRK N/A
- WGSWW N/A
- Fundamental
- Price
- STRK $92.65
- WGSWW $0.05
- Analyst Decision
- STRK
- WGSWW
- Analyst Count
- STRK 0
- WGSWW 0
- Target Price
- STRK N/A
- WGSWW N/A
- AVG Volume (30 Days)
- STRK 527.6K
- WGSWW 36.6K
- Earning Date
- STRK 04-30-2025
- WGSWW 02-18-2025
- Dividend Yield
- STRK N/A
- WGSWW N/A
- EPS Growth
- STRK N/A
- WGSWW N/A
- EPS
- STRK N/A
- WGSWW N/A
- Revenue
- STRK $463,456,000.00
- WGSWW $305,450,000.00
- Revenue This Year
- STRK N/A
- WGSWW N/A
- Revenue Next Year
- STRK N/A
- WGSWW N/A
- P/E Ratio
- STRK N/A
- WGSWW N/A
- Revenue Growth
- STRK N/A
- WGSWW 50.79
- 52 Week Low
- STRK $79.25
- WGSWW $0.17
- 52 Week High
- STRK $95.00
- WGSWW $0.21
- Technical
- Relative Strength Index (RSI)
- STRK N/A
- WGSWW N/A
- Support Level
- STRK N/A
- WGSWW N/A
- Resistance Level
- STRK N/A
- WGSWW N/A
- Average True Range (ATR)
- STRK 0.00
- WGSWW 0.00
- MACD
- STRK 0.00
- WGSWW 0.00
- Stochastic Oscillator
- STRK 0.00
- WGSWW 0.00
About STRK MICROSTRATEGY 8.00% SERIES A PERPETUAL STRIKE PFD
Strategy is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provide industry AI-powered enterprise analytics software.
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.